about
Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSData-intensive analysis of HIV mutations.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Acyclic nucleoside phosphonates: a key class of antiviral drugs.The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsDose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesProtection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirineCharacterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.Retrovirus reverse transcriptases containing a modified YXDD motif.Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.Bioinformatics approach to predicting HIV drug resistance.Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.Discovery and Development of Tenofovir Disoproxil Fumarate
P2860
Q28260539-4EEE8226-3552-4D7E-980C-3B0B997D4557Q30887525-9591FC3F-7FF1-4B3E-90C5-3EF38D257E20Q33889635-4B13E2E1-7262-43BF-B95D-CD146CA64720Q33900459-3C5FADF2-5D4D-480D-B70E-71A50F507416Q34464655-0D71B6BC-07D5-4EDE-A378-A186FB9E93E5Q34626108-8C98E2A8-D649-4C27-8920-93A40A6F1B01Q34647936-0B86C447-87D5-48F0-A05D-E59F23F2A4D7Q34937254-3F940688-EC96-453D-9181-AB547B5F15D2Q35042225-86A1D24E-1F00-4D4E-8EE8-3E36ABC81D42Q35140303-DB6A83AD-6AC5-4A61-A899-40FB64C47D7FQ35140323-3A0C87A7-5DFF-402F-B657-7B3424232BC5Q35689311-2AE05007-75E4-4FD3-88BB-6BB3EE044D48Q36076011-F75945C1-9CE4-4498-949C-A8C6E2008048Q36186797-C4327B89-F038-4F13-8E26-95D78A2A27BEQ36295410-155F4278-4EBD-4281-B8B1-8EF7CA84719CQ36411681-88974640-C5B8-429A-A538-6BD70BC61973Q37256312-81C639AB-9CB5-4C92-9CD2-F09D95E70F32Q37256719-A1B477F6-4D94-4A61-BA4D-3B8D7E1983E5Q37734688-39A81350-A97D-40F5-81F2-51E44E8AF6B2Q37859395-87D51359-1CFE-4306-8FE0-80AC951A48A5Q38262356-9AD98F69-637D-4B20-B1C0-0DDF4E9C9C4AQ38718627-2A6759E0-E6F7-414C-84B4-468F62AD4169Q40128143-3078542B-0B5A-43C2-9EC7-14B25F7ECDE3Q40783234-510509DD-4984-47FC-9C15-0B1B6C3F5534Q46914719-F397581D-DA67-42B6-B1FD-0D2E1C4FB499Q50145794-52B2BD2E-5AE3-4BC3-898E-5D43B93A641DQ52374199-38A79575-496C-4856-B7D8-7FA5968904F0Q56786248-03FF8719-8617-4B6B-AAFA-09D2988632B4
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Tenofovir resistance and resensitization
@en
type
label
Tenofovir resistance and resensitization
@en
prefLabel
Tenofovir resistance and resensitization
@en
P2093
P2860
P50
P1476
Tenofovir resistance and resensitization
@en
P2093
Barbara Schmidt
Hauke Walter
Joachim Selbig
Katharina Wolf
Rolf Kaiser
Wilco Keulen
P2860
P304
P356
10.1128/AAC.47.11.3478-3484.2003
P407
P577
2003-11-01T00:00:00Z